USFDA approves next-gen TKI Augtyro for treatment of solid tumors
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
EDQM has also issued a Certificate of Suitability for Allopurino
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Subscribe To Our Newsletter & Stay Updated